These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 10221346

  • 1. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
    Sato A, Suzuki Y, Saruta T.
    Hypertens Res; 1999 Mar; 22(1):17-22. PubMed ID: 10221346
    [Abstract] [Full Text] [Related]

  • 2. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension.
    Sato A, Hayashi M, Saruta T.
    Hypertens Res; 2002 Nov; 25(6):837-42. PubMed ID: 12484506
    [Abstract] [Full Text] [Related]

  • 3. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
    Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH.
    Circulation; 2003 Oct 14; 108(15):1831-8. PubMed ID: 14517164
    [Abstract] [Full Text] [Related]

  • 4. Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension.
    Azizi M, Perdrix L, Bobrie G, Frank M, Chatellier G, Ménard J, Plouin PF.
    J Hypertens; 2014 Oct 14; 32(10):2038-44; discussion 2044. PubMed ID: 24983187
    [Abstract] [Full Text] [Related]

  • 5. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy.
    Taniguchi I, Kawai M, Date T, Yoshida S, Seki S, Taniguchi M, Shimizu M, Mochizuki S.
    Circ J; 2006 Aug 14; 70(8):995-1000. PubMed ID: 16864931
    [Abstract] [Full Text] [Related]

  • 6. Aldosterone excess or escape: Treating resistant hypertension.
    Ubaid-Girioli S, Adriana de Souza L, Yugar-Toledo JC, Martins LC, Ferreira-Melo S, Coelho OR, Sierra C, Coca A, Pimenta E, Moreno H.
    J Clin Hypertens (Greenwich); 2009 May 14; 11(5):245-52. PubMed ID: 19534021
    [Abstract] [Full Text] [Related]

  • 7. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone.
    Ori Y, Chagnac A, Korzets A, Zingerman B, Herman-Edelstein M, Bergman M, Gafter U, Salman H.
    Nephrol Dial Transplant; 2013 Jul 14; 28(7):1787-93. PubMed ID: 23378418
    [Abstract] [Full Text] [Related]

  • 8. Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients.
    Sato A, Suzuki Y, Shibata H, Saruta T.
    Hypertens Res; 2000 Jan 14; 23(1):25-31. PubMed ID: 10737132
    [Abstract] [Full Text] [Related]

  • 9. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
    Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, O'Moore-Sullivan T, Marwick TH.
    JACC Cardiovasc Imaging; 2011 Dec 14; 4(12):1239-49. PubMed ID: 22172779
    [Abstract] [Full Text] [Related]

  • 10. Effect of combined spironolactone-β-blocker ± enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study).
    Dabrowski R, Borowiec A, Smolis-Bak E, Kowalik I, Sosnowski C, Kraska A, Kazimierska B, Wozniak J, Zareba W, Szwed H.
    Am J Cardiol; 2010 Dec 01; 106(11):1609-14. PubMed ID: 21094362
    [Abstract] [Full Text] [Related]

  • 11. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy.
    Sato A, Saruta T.
    J Int Med Res; 2001 Dec 01; 29(1):13-21. PubMed ID: 11277342
    [Abstract] [Full Text] [Related]

  • 12. Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis.
    Sato A, Funder JW, Saruta T.
    Am J Hypertens; 1999 Sep 01; 12(9 Pt 1):867-73. PubMed ID: 10509543
    [Abstract] [Full Text] [Related]

  • 13. Effects of enalapril, tempol, and eplerenone on salt-induced hypertension in dahl salt-sensitive rats.
    Bayorh MA, Mann G, Walton M, Eatman D.
    Clin Exp Hypertens; 2006 Feb 01; 28(2):121-32. PubMed ID: 16546838
    [Abstract] [Full Text] [Related]

  • 14. Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibition of the renin-angiotensin system.
    du Cailar G, Fesler P, Ribstein J, Mimran A.
    Hypertension; 2010 Nov 01; 56(5):865-70. PubMed ID: 20921428
    [Abstract] [Full Text] [Related]

  • 15. Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors.
    Kohno M, Yokokawa K, Minami M, Kano H, Yasunari K, Hanehira T, Yoshikawa J.
    Am J Med; 1999 May 01; 106(5):544-9. PubMed ID: 10335726
    [Abstract] [Full Text] [Related]

  • 16. High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients.
    Sato A, Takane H, Saruta T.
    Hypertens Res; 2001 Mar 01; 24(2):99-104. PubMed ID: 11325081
    [Abstract] [Full Text] [Related]

  • 17. A comparison study of the echocardiographic changes in hypertensive patients treated with telmisartan vs. enalapril.
    Hadi NR, Abdulzahra MS, Al-Huseini LM, Al-Aubaidy HA.
    Int J Cardiol; 2017 Mar 01; 230():269-274. PubMed ID: 28041700
    [Abstract] [Full Text] [Related]

  • 18. Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage.
    Bomback AS, Muskala P, Bald E, Chwatko G, Nowicki M.
    Clin Nephrol; 2009 Dec 01; 72(6):449-56. PubMed ID: 19954722
    [Abstract] [Full Text] [Related]

  • 19. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial.
    Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN.
    J Am Coll Cardiol; 2009 Aug 04; 54(6):505-12. PubMed ID: 19643310
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.